Molecular markers in gliomas: Impact for the clinician

Targeted Oncology

Volumn 5, Issue 3, 2010, Pages 201-210

  Hofer, Silvia ^b   Lassman, Andrew B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

1p19q; EGFR; Glioma; IDH; MGMT; Molecular; Predictive; Prognostic

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROCARBAZINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DNA METHYLATION; DRUG DOSE COMPARISON; GENE MUTATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GLIOMA; HUMANS; NEOPLASM PROTEINS; PHARMACOGENETICS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78049239492     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-010-0157-2     Document Type: Review

References (95)

1. HS Phillips S Kharbanda R Chen WF Forrest RH Soriano TD Wu A Misra JM Nigro H Colman L Soroceanu PM Williams Z Modrusan BG Feuerstein K Aldape 2006 Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 9 157 173 1:CAS:528:DC%2BD28XivFWjtL4%3D 10.1016/j.ccr.2006.02.019 16530701 (Pubitemid 43357943)
2. Cancer Genome Atlas Research Network 2008 Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 1061 1068 10.1038/nature07385
3. WJ Curran Jr CB Scott J Horton JS Nelson AS Weinstein AJ Fischbach CH Chang M Rotman SO Asbell RE Krisch, et al. 1993 Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials J Natl Cancer Inst 85 704 710 10.1093/jnci/85.9.704 8478956
4. RO Mirimanoff T Gorlia W Mason MJ Van den Bent RD Kortmann B Fisher M Reni AA Brandes J Curschmann S Villa G Cairncross A Allgeier D Lacombe R Stupp 2006 Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial J Clin Oncol 24 2563 2569 1:CAS:528:DC%2BD28XmtVOmt70%3D 10.1200/JCO.2005.04.5963 16735709 (Pubitemid 46630635)
5. CB Scott C Scarantino R Urtasun B Movsas CU Jones JR Simpson AJ Fischbach WJ Curran Jr 1998 Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06 Int J Radiat Oncol Biol Phys 40 51 55 1:STN:280:DyaK1c%2FotlShsg%3D%3D 9422557
6. IK Mellinghoff MY Wang I Vivanco DA Haas-Kogan S Zhu EQ Dia KV Lu K Yoshimoto JH Huang DJ Chute BL Riggs S Horvath LM Liau WK Cavenee PN Rao R Beroukhim TC Peck JC Lee WR Sellers D Stokoe M Prados TF Cloughesy CL Sawyers PS Mischel 2005 Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N Engl J Med 353 2012 2024 1:CAS:528:DC%2BD2MXht1SrtrrE 10.1056/NEJMoa051918 16282176 (Pubitemid 41609094)
7. JC Lee I Vivanco R Beroukhim JH Huang WL Feng RM DeBiasi K Yoshimoto JC King P Nghiemphu Y Yuza Q Xu H Greulich RK Thomas JG Paez TC Peck DJ Linhart KA Glatt G Getz R Onofrio L Ziaugra RL Levine S Gabriel T Kawaguchi K O'Neill H Khan LM Liau SF Nelson PN Rao P Mischel RO Pieper T Cloughesy DJ Leahy WR Sellers CL Sawyers M Meyerson IK Mellinghoff 2006 Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain PLoS Med 3 e485 10.1371/journal.pmed.0030485 17177598 (Pubitemid 46028511)
8. S Everhard G Kaloshi E Criniere A Benouaich-Amiel J Lejeune Y Marie M Sanson M Kujas K Mokhtari K Hoang-Xuan JY Delattre J Thillet 2006 MGMT methylation: a marker of response to temozolomide in low-grade gliomas Ann Neurol 60 740 743 1:CAS:528:DC%2BD2sXhsFeqtb8%3D 10.1002/ana.21044 17192931 (Pubitemid 46048490)
9. ME Hegi AC Diserens T Gorlia MF Hamou N de Tribolet M Weller JM Kros JA Hainfellner W Mason L Mariani JE Bromberg P Hau RO Mirimanoff JG Cairncross RC Janzer R Stupp 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997 1003 1:CAS:528:DC%2BD2MXit1Wktro%3D 10.1056/NEJMoa043331 15758010 (Pubitemid 40349502)
10. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 1:CAS:528:DC%2BD2MXit1Wksbk%3D 10.1056/NEJMoa043330 15758009 (Pubitemid 40349501)
11. R Stupp ME Hegi WP Mason MJ van den Bent MJ Taphoorn RC Janzer SK Ludwin A Allgeier B Fisher K Belanger P Hau AA Brandes J Gijtenbeek C Marosi CJ Vecht K Mokhtari P Wesseling S Villa E Eisenhauer T Gorlia M Weller D Lacombe JG Cairncross RO Mirimanoff 2009 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 459 466 1:CAS:528:DC%2BD1MXlsVKhs74%3D 10.1016/S1470-2045(09)70025-7 19269895
12. AL Rivera CE Pelloski MR Gilbert H Colman C De La Cruz EP Sulman BN Bekele KD Aldape 2010 MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma Neuro Oncol 12 116 121 1:CAS:528:DC%2BC3cXotFKitb8%3D 20150378
13. MJ van den Bent HJ Dubbink M Sanson CR van der Lee-Haarloo M Hegi JW Jeuken A Ibdaih AA Brandes MJ Taphoorn M Frenay D Lacombe T Gorlia WN Dinjens JM Kros 2009 MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951 J Clin Oncol 27 5881 5886 10.1200/JCO.2009.24.1034 19901104
14. W Wick C Hartmann C Engel M Stoffels J Felsberg F Stockhammer MC Sabel S Koeppen R Ketter R Meyermann M Rapp C Meisner RD Kortmann T Pietsch OD Wiestler U Ernemann M Bamberg G Reifenberger A von Deimling M Weller 2009 NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide J Clin Oncol 27 5874 5880 1:CAS:528:DC%2BC3cXhtVWis7g%3D 10.1200/JCO.2009.23.6497 19901110
15. R Stupp ME Hegi B Neyns R Goldbrunner U Schlegel PM Clement GG Grabenbauer AF Ochsenbein M Simon PY Dietrich T Pietsch C Hicking JC Tonn AC Diserens A Pica M Hermisson S Krueger M Picard M Weller 2010 Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma J Clin Oncol 28 16 2712 2718 1:CAS:528: DC%2BC3cXoslyktLs%3D 10.1200/JCO.2009.26.6650 20439646
16. SL Gerson 2004 MGMT: its role in cancer aetiology and cancer therapeutics Nat Rev Cancer 4 296 307 1:CAS:528:DC%2BD2cXis1Gmt70%3D 10.1038/nrc1319 15057289
17. M Preusser R Charles Janzer J Felsberg G Reifenberger MF Hamou AC Diserens R Stupp T Gorlia C Marosi H Heinzl JA Hainfellner M Hegi 2008 Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker Brain Pathol 18 520 532 1:CAS:528:DC%2BD1cXht1CjtLvM 18400046
18. J Felsberg M Rapp S Loeser R Fimmers W Stummer M Goeppert HJ Steiger B Friedensdorf G Reifenberger MC Sabel 2009 Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients Clin Cancer Res 15 6683 6693 1:CAS:528:DC%2BD1MXhtlCjsrfP 10.1158/1078-0432.CCR-08-2801 19861461
19. W Wick M Platten M Weller 2009 New (alternative) temozolomide regimens for the treatment of glioma Neuro Oncol 11 69 79 1:CAS:528:DC%2BD1MXjtFKntr8%3D 10.1215/15228517-2008-078 18772354
20. JL Clarke FM Iwamoto J Sul K Panageas AB Lassman LM DeAngelis A Hormigo CP Nolan I Gavrilovic S Karimi LE Abrey 2009 Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma J Clin Oncol 27 3861 3867 1:CAS:528: DC%2BD1MXhtFaitrrJ 10.1200/JCO.2008.20.7944 19506159
21. JR Perry K Belanger WP Mason D Fulton P Kavan J Easaw C Shields S Kirby DR Macdonald DD Eisenstat B Thiessen P Forsyth JF Pouliot 2010 Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study J Clin Oncol 28 2051 2057 1:CAS:528:DC%2BC3cXmtlSksrk%3D 10.1200/JCO.2009.26.5520 20308655
22. DS Kong JI Lee JH Kim ST Kim WS Kim YL Suh SM Dong DH Nam 2010 Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma Neuro Oncol 12 289 296 1:CAS:528:DC%2BC3cXot1Gmurg%3D 20167817
23. W Wick JP Steinbach WM Kuker J Dichgans M Bamberg M Weller 2004 One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma Neurology 62 2113 2115 1:CAS:528:DC%2BD2cXktVKgtrs%3D 15184628
24. Brada M, for the BR12 collaborators (2008) A randomised trial of Procarbazine, CCNU and Vincristine (PCV) vs. Temozolomide (5-day or 21-day schedule) for recurrent high-grade glioma (MRC BR12) [Abstract O21]. Neuro Oncol 10:1067
25. Riemenschneider MJ, Hegi ME, Reifenberger G (2010) MGMT promoter methylation in malignant gliomas. Targ Oncol, in press. doi: 10.1007/s11523-010-0153-6
26. CBTRUS: Central Brain Tumor Registry of the United States 2008 statistical report: primary brain tumors in the Uninted States. www.cbtrus.org/reports/reports.html. Accessed August 12, 2010
27. J Reifenberger G Reifenberger L Liu CD James W Wechsler VP Collins 1994 Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p Am J Pathol 145 1175 1190 1:CAS:528:DyaK2MXit1Wksb8%3D 7977648
28. JG Cairncross K Ueki MC Zlatescu DK Lisle DM Finkelstein RR Hammond JS Silver PC Stark DR Macdonald Y Ino DA Ramsay DN Louis 1998 Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas J Natl Cancer Inst 90 1473 1479 1:STN:280: DyaK1cvkslejug%3D%3D 10.1093/jnci/90.19.1473 9776413
29. RB Jenkins H Blair KV Ballman C Giannini RM Arusell M Law H Flynn S Passe S Felten PD Brown EG Shaw JC Buckner 2006 A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma Cancer Res 66 9852 9861 1:CAS:528:DC%2BD28XhtVyiur3I 10.1158/0008-5472.CAN-06-1796 17047046 (Pubitemid 44672036)
30. JS Smith A Perry TJ Borell HK Lee J O'Fallon SM Hosek D Kimmel A Yates PC Burger BW Scheithauer RB Jenkins 2000 Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas J Clin Oncol 18 636 645 1:STN:280:DC%2BD3c7itVyrsA%3D%3D 10653879
31. AB Lassman KS Panageas FM Iwamoto LM DeAngelis AL Rivera KD Aldape TF Cloughesy A Eichler DN Louis N Paleologos B Fisher L Ashby GB Roldan JG Cairncross PY Wen D Schiff BG Rocque HI Robins MC Chamberlain W Mason S Weaver RM Green FG Kamar S Jhanwar MK Rosenblum LE Abrey 2009 International retrospective study of 1000+ adults with anaplastic oligodendroglial tumors [Abstract 283] Neuro Oncol 11 629
32. DN Louis H Ohgaki OD Wiestler, et al. 2007 The 2007 WHO Classification of Tumours of the Central Nervous System Acta Neuropathol 114 2 97 109 10.1007/s00401-007-0243-4 17618441 (Pubitemid 47103521)
33. PC Burger 2002 What is an oligodendroglioma? Brain Pathol 12 257 259 10.1111/j.1750-3639.2002.tb00440.x 11958379
34. C Giannini PC Burger BA Berkey JG Cairncross RB Jenkins M Mehta WJ Curran K Aldape 2008 Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402 Brain Pathol 18 360 369 10.1111/j.1750-3639.2008.00129.x 18371182 (Pubitemid 351782844)
35. C Giannini BW Scheithauer AL Weaver PC Burger JM Kros S Mork MB Graeber S Bauserman JC Buckner J Burton R Riepe HD Tazelaar AG Nascimento T Crotty GL Keeney P Pernicone H Altermatt 2001 Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading J Neuropathol Exp Neurol 60 248 262 1:STN:280:DC%2BD3M7osVOitA%3D%3D 11245209
36. JM McDonald SJ See IW Tremont H Colman MR Gilbert M Groves PC Burger DN Louis C Giannini G Fuller S Passe H Blair RB Jenkins H Yang A Ledoux J Aaron U Tipnis W Zhang K Hess K Aldape 2005 The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors Cancer 104 1468 1477 1:CAS:528:DC%2BD2MXhtFahsb%2FL 10.1002/cncr.21338 16088966 (Pubitemid 41356162)
37. SW Coons PC Johnson BW Scheithauer AJ Yates DK Pearl 1997 Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas Cancer 79 1381 1393 1:STN:280:DyaK2s3js1Cltw%3D%3D 10.1002/(SICI)1097-0142(19970401)79:7<1381::AID-CNCR16>3.0.CO;2-W 9083161 (Pubitemid 27143246)
38. J Kros T Gorlia M van den Bent 2007 Panel review of anaplastic oligodendroglioma from EORTC trial 26951: consensus in diagnosis and influence of 1p/19q [abstract PA-16] Neuro Oncol 9 545
39. K Aldape PC Burger A Perry 2007 Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma Arch Pathol Lab Med 131 242 251 1:CAS:528:DC%2BD2sXisFylsrY%3D 17284109
40. K Kouwenhoven T Gorlia J Kros A Carpentier A Brandes M Sanson M Taphoorn H Teepen H Bernsen M Frenay C Tijssen W Grisold L Sipos R Stupp C Vecht A Allgeier D Lacombe M van den Bent 2007 EORTC 26951: prognosis of oligodendroglial tumors is an interplay of molecular, histological, and clinical characteristics [abstract PA-18] Neuro Oncol 9 546
41. T Homma T Fukushima S Vaccarella Y Yonekawa PL Di Patre S Franceschi H Ohgaki 2006 Correlation among pathology, genotype, and patient outcomes in glioblastoma J Neuropathol Exp Neurol 65 846 854 1:CAS:528:DC%2BD28XhtVGitrrF 10.1097/01.jnen.0000235118.75182.94 16957578 (Pubitemid 44371230)
42. LW Pinto MB Araujo AL Vettore L Wernersbach AC Leite LM Chimelli FA Soares 2008 Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis Virchows Arch 452 481 490 10.1007/s00428-007-0562-9 18351387
43. JA Kraus K Lamszus N Glesmann M Beck M Wolter M Sabel D Krex T Klockgether G Reifenberger U Schlegel 2001 Molecular genetic alterations in glioblastomas with oligodendroglial component Acta Neuropathol 101 311 320 1:CAS:528:DC%2BD3MXisFOmtLk%3D 11355302 (Pubitemid 32372420)
44. SH Bigner MR Matthews BK Rasheed RN Wiltshire HS Friedman AH Friedman TT Stenzel DM Dawes RE McLendon DD Bigner 1999 Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization Am J Pathol 155 375 386 1:CAS:528:DyaK1MXls1Whs7s%3D 10433931
45. J He K Mokhtari M Sanson Y Marie M Kujas S Huguet P Leuraud L Capelle JY Delattre J Poirier K Hoang-Xuan 2001 Glioblastomas with an oligodendroglial component: a pathological and molecular study J Neuropathol Exp Neurol 60 863 871 1:CAS:528:DC%2BD3MXnt1Snt7c%3D 11556543
46. G Cairncross B Berkey E Shaw R Jenkins B Scheithauer D Brachman J Buckner K Fink L Souhami N Laperierre M Mehta W Curran 2006 Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 J Clin Oncol 24 2707 2714 1:CAS:528:DC%2BD28XntV2hurg%3D 10.1200/JCO.2005.04.3414 16782910 (Pubitemid 46630566)
47. MJ van den Bent AF Carpentier AA Brandes M Sanson MJ Taphoorn HJ Bernsen M Frenay CC Tijssen W Grisold L Sipos H Haaxma-Reiche JM Kros MC van Kouwenhoven CJ Vecht A Allgeier D Lacombe T Gorlia 2006 Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial J Clin Oncol 24 2715 2722 10.1200/JCO.2005.04.6078 16782911 (Pubitemid 46630567)
48. FM Iwamoto L Nicolardi A Demopoulos V Barbashina P Salazar M Rosenblum A Hormigo 2008 Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas J Neurooncol 88 293 298 10.1007/s11060-008-9563-z 18345516
49. D Krex B Klink C Hartmann A von Deimling T Pietsch M Simon M Sabel JP Steinbach O Heese G Reifenberger M Weller G Schackert 2007 Long-term survival with glioblastoma multiforme Brain 130 2596 2606 10.1093/brain/awm204 17785346 (Pubitemid 47511715)
50. M Weller H Berger C Hartmann J Schramm M Westphal M Simon R Goldbrunner D Krex JP Steinbach CB Ostertag M Loeffler T Pietsch A von Deimling 2007 Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 13 6933 6937 1:CAS:528:DC%2BD2sXhtlyit7fL 10.1158/1078-0432.CCR- 07-0573 18056167 (Pubitemid 350276872)
51. MJ van den Bent LH Looijenga K Langenberg W Dinjens W Graveland L Uytdewilligen PA Sillevis Smitt RB Jenkins JM Kros 2003 Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features Cancer 97 1276 1284 10.1002/cncr.11187 12599236 (Pubitemid 36237315)
52. LE Abrey DN Louis N Paleologos AB Lassman JJ Raizer W Mason J Finlay DR Macdonald LM Deangelis JG Cairncross 2007 Survey of treatment recommendations for anaplastic oligodendroglioma Neuro-oncol 9 314 318 1:CAS:528: DC%2BD2sXpt1agtr8%3D 10.1215/15228517-2007-002 17435180 (Pubitemid 47169664)
53. MD Walker E Alexander Jr WE Hunt CS MacCarty MS Mahaley Jr J Mealey Jr HA Norrell G Owens J Ransohoff CB Wilson EA Gehan TA Strike 1978 Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial J Neurosurg 49 333 343 1:STN:280:DyaE1c3ksVWrug%3D%3D 10.3171/jns.1978.49.3.0333 355604
54. MD Walker SB Green DP Byar E Alexander Jr U Batzdorf WH Brooks WE Hunt CS MacCarty MS Mahaley Jr J Mealey Jr G Owens J Ransohoff 2nd JT Robertson WR Shapiro KR Smith Jr CB Wilson TA Strike 1980 Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery N Engl J Med 303 1323 1329 1:STN:280:DyaL3M%2Flt1Wiuw%3D%3D 10.1056/NEJM198012043032303 7001230
55. LM DeAngelis PC Burger SB Green JG Cairncross 1998 Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol 44 691 695 1:STN:280: DyaK1cvkvFOhsg%3D%3D 10.1002/ana.410440418 9778271 (Pubitemid 28477860)
56. JG Cairncross DR Macdonald 1988 Successful chemotherapy for recurrent malignant oligodendroglioma Ann Neurol 23 360 364 1:STN:280:DyaL1c3ltV2ntA%3D%3D 10.1002/ana.410230408 3382171
57. G Cairncross D Macdonald S Ludwin D Lee T Cascino J Buckner D Fulton E Dropcho D Stewart C Schold Jr, et al. 1994 Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 12 2013 2021 1:STN:280:DyaK2M%2Fhs1ylsQ%3D%3D 7931469
58. DR Macdonald LE Gaspar JG Cairncross 1990 Successful chemotherapy for newly diagnosed aggressive oligodendroglioma Ann Neurol 27 573 574 1:STN:280:DyaK3c3pslGlsw%3D%3D 10.1002/ana.410270519 2360797
59. Y Ino RA Betensky MC Zlatescu H Sasaki DR Macdonald AO Stemmer-Rachamimov DA Ramsay JG Cairncross DN Louis 2001 Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis Clin Cancer Res 7 839 845 1:STN:280:DC%2BD3M3pvFGqtw%3D%3D 11309331
60. G Cairncross M Wang S Chang E Shaw R Jenkins B Scheithauer J Buckner K Fink M Mehta W Curran 2008 A randomized trial of chemotherapy plus radiotherapy (RT) versus RT alone for anaplastic oligodendroglioma (RTOG 9402): the perspective of longer follow-up Int J Rad Oncol Bio Phys 72 S7 S8
61. L Douw M Klein SS Fagel J van den Heuvel MJ Taphoorn NK Aaronson TJ Postma WP Vandertop JJ Mooij RH Boerman GN Beute JD Sluimer BJ Slotman JC Reijneveld JJ Heimans 2009 Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up Lancet Neurol 8 810 818 10.1016/S1474-4422(09)70204-2 19665931
62. LM DeAngelis JY Delattre JB Posner 1989 Radiation-induced dementia in patients cured of brain metastases Neurology 39 789 796 1:STN:280: DyaL1M3mt1Kisw%3D%3D 2725874
63. LM DeAngelis 2009 Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected] J Clin Oncol 27 5861 5862 10.1200/JCO.2009.24.5985 19901101
64. H Yan DW Parsons G Jin R McLendon BA Rasheed W Yuan I Kos I Batinic-Haberle S Jones GJ Riggins H Friedman A Friedman D Reardon J Herndon KW Kinzler VE Velculescu B Vogelstein DD Bigner 2009 IDH1 and IDH2 mutations in gliomas N Engl J Med 360 765 773 1:CAS:528:DC%2BD1MXitFWru7o%3D 10.1056/NEJMoa0808710 19228619
65. C Hartmann J Meyer J Balss D Capper W Mueller A Christians J Felsberg M Wolter C Mawrin W Wick M Weller C Herold-Mende A Unterberg JW Jeuken P Wesseling G Reifenberger A von Deimling 2009 Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1, 010 diffuse gliomas Acta Neuropathol 118 469 474 10.1007/s00401-009-0561-9 19554337
66. M Sanson Y Marie S Paris A Idbaih J Laffaire F Ducray S El Hallani B Boisselier K Mokhtari K Hoang-Xuan JY Delattre 2009 Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas J Clin Oncol 27 4150 4154 1:CAS:528:DC%2BD1MXhtF2jtLrP 10.1200/JCO.2009.21.9832 19636000
67. M Labussiere A Idbaih XW Wang Y Marie B Boisselier C Falet S Paris J Laffaire C Carpentier E Criniere F Ducray S El Hallani K Mokhtari K Hoang-Xuan JY Delattre M Sanson 2010 All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 Neurology 74 1886 1890 1:CAS:528:DC%2BC3cXntF2gtbw%3D 10.1212/WNL. 0b013e3181e1cf3a 20427748
68. S Zhao Y Lin W Xu W Jiang Z Zha P Wang W Yu Z Li L Gong Y Peng J Ding Q Lei KL Guan Y Xiong 2009 Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha Science 324 261 265 1:CAS:528:DC%2BD1MXktFals7g%3D 10.1126/science.1170944 19359588
69. L Dang DW White S Gross BD Bennett MA Bittinger EM Driggers VR Fantin HG Jang S Jin MC Keenan KM Marks RM Prins PS Ward KE Yen LM Liau JD Rabinowitz LC Cantley CB Thompson MG Vander Heiden SM Su 2009 Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 739 744 1:CAS:528:DC%2BD1MXhsVGlurzE 10.1038/nature08617 19935646
70. A Korshunov J Meyer D Capper A Christians M Remke H Witt S Pfister A von Deimling C Hartmann 2009 Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma Acta Neuropathol 118 401 405 1:CAS:528:DC%2BD1MXptVGjt7c%3D 10.1007/s00401-009-0550-z 19543740
71. MJ van den Bent HJ Dubbink Y Marie AA Brandes MJ Taphoorn P Wesseling M Frenay CC Tijssen D Lacombe A Idbaih R van Marion JM Kros WN Dinjens T Gorlia M Sanson 2010 IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group Clin Cancer Res 16 1597 1604 10.1158/1078-0432.CCR-09-2902 20160062
72. M Labussiere A Idbaih XW Wang Y Marie B Boisselier C Falet S Paris J Laffaire C Carpentier E Criniere F Ducray S El Hallani K Mokhtari K Hoang-Xuan JY Delattre M Sanson 2010 All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 Neurology 74 1886 1890 1:CAS:528:DC%2BC3cXntF2gtbw%3D 10.1212/WNL. 0b013e3181e1cf3a 20427748
73. CT Kuan CJ Wikstrand DD Bigner 2001 EGF mutant receptor vIII as a molecular target in cancer therapy Endocr Relat Cancer 8 83 96 1:CAS:528:DC%2BD3MXls1Kqtbk%3D 10.1677/erc.0.0080083 11397666 (Pubitemid 32641351)
74. KB Fallon CA Palmer KA Roth LB Nabors W Wang M Carpenter R Banerjee P Forsyth K Rich A Perry 2004 Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas J Neuropathol Exp Neurol 63 314 322 1:CAS:528:DC%2BD2cXjs1Wgs78%3D 15099021
75. K Hoang-Xuan J He S Huguet K Mokhtari Y Marie M Kujas P Leuraud L Capelle JY Delattre J Poirier P Broet M Sanson 2001 Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression Neurology 57 1278 1281 1:STN:280:DC%2BD3Mrlt12isQ%3D%3D 11591848
76. CE Pelloski KV Ballman AF Furth L Zhang E Lin EP Sulman K Bhat JM McDonald WK Yung H Colman SY Woo AB Heimberger D Suki MD Prados SM Chang FG Barker 2nd JC Buckner CD James K Aldape 2007 Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma J Clin Oncol 25 2288 2294 1:CAS:528:DC%2BD2sXnsVShu78%3D 10.1200/JCO.2006.08.0705 17538175 (Pubitemid 46954657)
77. H Ohgaki P Dessen B Jourde S Horstmann T Nishikawa PL Di Patre C Burkhard D Schuler NM Probst-Hensch PC Maiorka N Baeza P Pisani Y Yonekawa MG Yasargil UM Lutolf P Kleihues 2004 Genetic pathways to glioblastoma: a population-based study Cancer Res 64 6892 6899 1:CAS:528:DC%2BD2cXotFalsrc%3D 10.1158/0008-5472.CAN-04-1337 15466178 (Pubitemid 39330996)
78. L Liu LM Bäcklund BR Nilsson D Grandér K Ichimura HM Goike VP Collins 2005 Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas J Mol Med 83 11 917 926 1:CAS:528:DC%2BD2MXht1SksbjI 10.1007/s00109-005-0700-2 16133418 (Pubitemid 41598692)
79. Lai R, Recht LD, Reardon DA, Paleologos N, Groves MD, Rosenfeld MR, Meech S, Davis TA, Pavlov D, Sampson JH (2010) Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM) [Abstract]. J Clin Oncol 28: suppl; abstract 2014
80. JJ Raizer LE Abrey AB Lassman SM Chang KR Lamborn JG Kuhn WK Yung MR Gilbert KA Aldape PY Wen HA Fine M Mehta LM Deangelis F Lieberman TF Cloughesy HI Robins J Dancey MD Prados 2010 A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy Neuro Oncol 12 95 103 1:CAS:528:DC%2BC3cXjvFCnt7Y%3D 20150372
81. Lieberman FS, Cloughesy T, Malkin M, Fine H, Fink K, Junck L, Kuhn J, Mehta M, Wen P, Prados M (2003) Phase I-II study of ZD-1839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy [abstract]. J Clin Oncol 22:105 (abstact 421)
82. JN Rich DA Reardon T Peery JM Dowell JA Quinn KL Penne CJ Wikstrand LB Van Duyn JE Dancey RE McLendon JC Kao TT Stenzel BK Ahmed Rasheed SE Tourt-Uhlig JE Herndon 2nd JJ Vredenburgh JH Sampson AH Friedman DD Bigner HS Friedman 2004 Phase II trial of gefitinib in recurrent glioblastoma J Clin Oncol 22 133 142 1:CAS:528:DC%2BD2cXpsVKhsr8%3D 10.1200/JCO.2004.08.110 14638850 (Pubitemid 41095125)
83. DM Peereboom DR Shepard MS Ahluwalia CJ Brewer N Agarwal GH Stevens JH Suh SA Toms MA Vogelbaum RJ Weil P Elson GH Barnett 2010 Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme J Neurooncol 98 93 99 1:CAS:528:DC%2BC3cXntVClu74%3D 10.1007/s11060-009-0067-2 19960228
84. Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, Reardon DA, Prados MD (2010) Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol doi: 10.1093/neuonc/noq072
85. MA Vogelbaum G Peerboom G Stevens G Barnett C Brewer 2004 Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent Glioblastoma Multiforme: Interim results [abstract] J Clin Oncol 22 1558
86. Lassman AB, Rossi MR, Raizer JJ, Abrey LE, Lieberman FS, Grefe CN, Lamborn K, Pao W, Shih AH, Kuhn JG, Wilson R, Nowak NJ, Cowell JK, DeAngelis LM, Wen P, Gilbert MR, Chang S, Yung WA, Prados M, Holland EC (2005) Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 11:7841-7850 [published correction appears in Clin Cancer Res 2005;7812(7841):7322]
87. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB (2010) High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol doi: 10.1007/s11060-010-0128-6
88. S Hofer K Frei 2007 Gefitinib concentrations in human glioblastoma tissue J Neurooncol 82 175 176 10.1007/s11060-006-9257-3 17008949 (Pubitemid 46431861)
89. J Kuhn HI Robins M Mehta H Fine T Cloughesy PY Wen S Chang LM DeAngelis F Lieberman D Reardon LE Abrey AB Lassman K Aldape WK Yung J Dancey K Lamborn M Prados 2008 Tumor sequestration of lapatinib (NABTC 04-01) [Abstract ET-05] Neuro Oncol 10 783
90. DA Haas-Kogan MD Prados T Tihan DA Eberhard N Jelluma ND Arvold R Baumber KR Lamborn A Kapadia M Malec MS Berger D Stokoe 2005 Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib J Natl Cancer Inst 97 880 887 1:CAS:528:DC%2BD2MXmtVahtrs%3D 10.1093/jnci/dji161 15956649 (Pubitemid 41417939)
91. A Custodio A Calles P Perez-Segura 2010 Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN Clin Transl Oncol 12 310 314 1:STN:280:DC%2BC3czjtlalsQ%3D%3D 10.1007/s12094-010- 0510-z 20462843
92. AA Brandes E Franceschi A Tosoni ME Hegi R Stupp 2008 Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments Clin Cancer Res 14 957 960 1:CAS:528:DC%2BD1cXhvF2ntL0%3D 10.1158/1078-0432.CCR-07- 1810 18281526 (Pubitemid 351302539)
93. MJ van den Bent AA Brandes R Rampling MC Kouwenhoven JM Kros AF Carpentier PM Clement M Frenay M Campone JF Baurain JP Armand MJ Taphoorn A Tosoni H Kletzl B Klughammer D Lacombe T Gorlia 2009 Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034 J Clin Oncol 27 1268 1274 10.1200/JCO.2008.17.5984 19204207
94. Wick W, Weller M, van den Bent M, Stupp R (2010) Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol 28:e188-189; author reply e190-182
95. A Lai E Filka B McGibbon PL Nghiemphu C Graham WH Yong P Mischel LM Liau M Bergsneider W Pope M Selch T Cloughesy 2008 Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability Int J Radiat Oncol Biol Phys 71 1372 1380 1:CAS:528:DC%2BD1cXoslWqsLo%3D 18355978